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Abstract
Objectives—Platinum-based chemotherapy with bevacizumab is a standard therapy for patients 
with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. 
Mechanisms of resistance to bevacizumab include increased VEGF signaling or activation of 
VEGF receptors. Pazopanib is a multi-targeted VEGF receptor tyrosine kinase with single agent 
activity in NSCLC.
Materials and methods—Stage IIIB/IV patients with adequate organ function, who progressed 
on a bevacizumab containing therapy were eligible if it had been ≤8 weeks since the last 
bevacizumab treatment. The primary end-point was disease control rate (DCR), defined as partial 
or complete response, or stable disease for ≥12 weeks. Patients were assessed radiographically 
every 2 cycles (6 weeks). A Simon 2-stage design was used, and if in the first stage ≤4 of 17 
patients experienced disease control the trial was to have been stopped for futility. An unplanned 
analysis was performed after 15 patients were evaluable secondary to slow accrual.
Results—Between December 2010 and November 2013, 15 patients were treated on trial. The 
median age was 61 years (range 39–74), and all patients had stage IV disease. Of the 15 patients, 4 
discontinued therapy prior to cycle 2 evaluation due to adverse events (n = 3) and medical illness 
(n = 1), 5 patients had progressive disease, 4 patients had stable disease for <12 weeks, and 2 
patients had stable disease for ≥12 weeks. No responses were observed. The DCR observed was 
13% (2/15), and the trial did not meet the criteria to proceed to the second stage. Episodes of grade 
3 treatment related toxicities observed included: increased ALT (n = 2), increased AST (n = 1), 
anorexia (n = 3), fatigue (n = 3), hypertension (n = 1), infection (n = 1), mucositis (n = 2), nausea 
(n = 3), pericardial effusion (n = 1), and vomiting (n = 1).
Conclusion—Pazopanib has limited activity in NSCLC-NS in patients who have experienced 
disease progression on bevacizumab.
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Lung cancer remains the leading cause of cancer deaths in the United States, and is a leading 
cause of cancer deaths globally [1,2]. The majority patients with lung cancer have the non-
small cell lung cancer (NSCLC) subtype, and have advanced stage disease at the time of 
diagnosis. The goals of treatment for patients with NSCLC and advanced stage disease are 
to extend overall survival (OS),improve quality of life, and reduce disease-related 
symptoms. For the minority of patients with an epidermal growth factor receptor(EGFR) 
tyrosine kinase mutation or an anaplastic lymphoma kinase(ALK) rearrangement first-line 
targeted therapy is an option [3, 4]. For patients with NSCLC without an EGFR or ALK 
molecular alteration treatment with platinum-based chemotherapy remains the standard of 
care. For patients with NSCLC and non-squamous histology, treatment with platinum-based 
therapy with bevacizumab, a monoclonal antibody against vascular endothelial growth factor 
A (VEGF), is a treatment option. Two phase-III trials compared platinum-based therapy with 
and without bevacizumab. Both trials demonstrated a statistically significant improvement in 
objective response rate (ORR) and progression-free survival (PFS), and one trial also 
demonstrated a statistically significant improvement in OS [5–7]. Unfortunately there is no 
predictive biomarker for bevacizumab benefit.
The median PFS observed in the phase III trials of platinum-based chemotherapy with 
bevacizumab was approximately six months, suggesting that acquired resistance to 
bevacizumab occurs in a relatively short period of time [5, 7]. The mechanisms of 
bevacizumab resistance remain unclear. Candidate mechanisms include increased production 
of VEGF, increased expression of VEGF receptors, and the development of non-VEGF 
dependent mechanisms of stimulating tumor vascular growth [8]. Multi-targeted vascular 
endothelial growth factor receptor inhibitors inhibit the VEGF receptor tyrosine kinases. 
This trial was designed in 2009 following the presentation of data demonstrating that 
pazopanib has single agent activity in NSCLC [9]. We hypothesized that patients who 
previously benefitted from and tolerated the VEGF antibody bevacizumab might, upon 
disease progression, have a higher probability of benefit from intracellular tyrosine kinase 
inhibition of VEGF.
1. Patients and methods
Patients with stage IIIB or IV NSCLC with non-squamous histology who had documented 
radiographic progression on a bevacizumab-containing therapy, and who were ≤8 weeks 
since last bevacizumab treatment were eligible for enrollment. Other eligibility criteria 
included an Eastern Cooperative Oncology Group performance status of 0–2, measurable 
disease by Response Evaluation criteria in Solid Tumors (RECIST) version 1.1, and 
adequate organ function [10]. Patients with treated brain metastases who were asymptomatic 
and who were not requiring steroids were eligible.
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Patients with gastrointestinal abnormalities that could increase the risk of bleeding (e.g. 
peptic ulcer disease, known intraluminal metastatic lesion, and active inflammatory bowel 
disease), history of GI bleeding within the previous 6 months, prolonged QT interval, 
unstable cardiovascular disease, a cerebrovascular event with in the previous 6 months, 
uncontrolled hypertension, hemoptysis within the previous 6 weeks, or lesions infiltrating 
the major pulmonary vessels were excluded. Concomitant use of medications that inhibit the 
CYP2A4, CYP2C8, and CYP2D6 was prohibited 14 days prior to starting the study drug, 
and patients who were not able to discontinue the concomitant medication were ineligible. 
The trial was reviewed by the Institutional Review Board of all the participating centers, and 
all patients provided written informed consent prior to any study related tests or procedures. 
The trial was registered at Clinicaltrials.gov (National Clinical Trials number: 
NCT01262820)[11].
2. Treatment
Patients who were enrolled and eligible for the trial were treated with pazopanib 800 mg 
daily. Cycle duration was 21 days. Blood pressure was monitored weekly for the first 6 
weeks. Other toxicities, including laboratory evaluations of complete blood count, urine 
protein/creatinine ratio, serum chemistries and liver function tests were evaluated every 3 
weeks. Patients underwent disease assessment with radiographic imaging every 6 weeks. 
Patients continued on pazopanib until disease progression, unacceptable toxicity, study 
withdrawal or death.
3. Study design
The primary end-point was the disease control rate (DCR) defined as a complete response, 
partial response, or stable disease of ≥12 weeks duration. Patients who discontinued therapy 
for reasons other than disease progression were censored at the date of treatment 
discontinuation. The null hypothesis that the DCR was less than 25% was tested against the 
one-sided alternative that the DCR was higher than 25%. A Simon two-stage mini–max 
design was used, and if disease was not controlled in at least 5 of the first 17 patients, the 
trial would have been terminated [12]. If at least 5 of the first 17 patients experienced 
disease control, 19 additional patients were to be enrolled (a total of 36 patients). This 
design yielded a type I error rate of 0.05, and power of 0.80 when the true disease control 
rate was 45%. Trial accrual was slower than anticipated and the trial was analyzed after 15 
patients were evaluable to assess whether enrollment should continue.
4. Results
Between April 2010 and January 2014, 22 patients provided informed consent for the trial; 7 
patients were considered ineligible and 15 patients were enrolled and treated on trial. 
Reasons for ineligibility were concomitant medication (n = 2), >8 weeks from last 
bevacizumab treatment (n = 2), concurrent medical illness (n = 2), and did not meet multiple 
eligibility criteria (n = 1).The median age was 61 years (range 39–74), 8 patients were 
women, and all patients had stage IV disease. Of the 15 patients, 4 discontinued therapy 
prior to cycle 2 disease evaluation due to adverse events (n = 3) and medical illness (n = 1), 
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and 5 patients experienced progressive disease. Four patients experienced stable disease-2 
patients for <12 weeks and 2 patients for ≥12 weeks. The DCR observed was 13% (95% 
confidence interval (CI), 0.02–0.40).The median progression-free and overall survivals 
observed were 10.9 weeks (95% CI, 8.1–18.9) and 24.1 weeks (95% CI, 20.3–
33.7),respectively.
The reasons for treatment discontinuation were disease progression (n = 9), adverse events 
(n = 4), and medical illness (n = 2). Episodes of grade 3 treatment related toxicities observed 
include increased alanine aminotransferase (n = 2), increased aspartate aminotransferase (n 
= 1), anorexia (n = 3), fatigue (n = 3), hypertension (n = 1), infection (n = 1), mucositis (n = 
2), nausea (n = 3), pericardial effusion (n = 1), and vomiting (n = 1).
5. Discussion
This trial accrued 15 of the planned 17 patients in the first-stage of the Simon two-stage 
design. Early data analysis performed due to slow accrual demonstrated insufficient efficacy 
to justify additional accrual. This data suggests that pazopanib has limited activity in non-
squamous NSCLC patients who have experienced disease progression on a bevacizumab-
containing regimen. An ongoing European Organization of Research and Treatment of 
Cancer (EORTC) phase II/III study (NCT01208064) evaluates pazopanib as compared to 
placebo in patients who have not progressed after four cycles of first-line chemotherapy 
[11]. The primary end-point is OS, and the results of this trial will better define the role of 
pazopanib in advanced NSCLC.
Since the design of this trial several studies have evaluated the efficacy of multi-targeted 
tyrosine kinase inhibitors of VEGF as single agents or in combination with chemotherapy or 
another targeted agent. Phase III trials have demonstrated improvements in PFS, however, 
none have revealed an improvement in OS in the intent-to-treat patient population [13–19]. 
One trial compared docetaxel with the multi-targeted tyrosine kinase inhibitor nintedanib to 
docetaxel with placebo and showed a statistically significant survival advantage in the 
adenocarcinoma subset [17]. However, none of these trials enriched for patients who were 
previously treated with bevacizumab. In previous trials 3–8% of patients enrolled were 
previously treated with bevacizumab [16–18]. At this time there is limited data investigating 
the impact of prior bevacizumab therapy on second-line anti-angiogenic therapy.
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